© Alexis Haulot
OncoDNA , specializing in profiling tests and the interpretation of data for the treatment of advanced cancers, has just completed a series B funding round of 19 million euros. This fundraising, which includes only private equity, should support growth abroad, thanks to the extension of the use of the OncoKDM platform, a dematerialized clinical decision support tool. An internationalization which should involve the engagement of about fifteen people.